All In Biotech

Drug Trial Radar · NCT06041035

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

A Phase IB/II Clinical Study to Assess the Efficacy and Safety of QLS31905 in Combination With Chemotherapy as First-line Treatment in Patients With Claudin 18.2 (CLDN18.2) Positive Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

115

Planned (sponsor's estimate)

Start

Oct 2023

Primary completion

Oct 2024

Study completion Oct 2025

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of QLS31905 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.

Conditions

  • Solid Tumor

Interventions

  • QLS31905Drug

    Administered as an intravenous infusion.

  • Nab paclitaxelDrug

    125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.

  • GemcitabineDrug

    1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.

  • OxaliplatinDrug

    85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.

  • CapecitabineDrug

    1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.

  • CisplatinDrug

    25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) (Part A)Time frame: Approximately 12 months
  2. Phase 2 Recommended Dose(RP2D)(Part A)Time frame: Approximately 12 months
  3. Objective response rate (ORR)(Part B)Time frame: Approximately 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.